Background {#Sec1}
==========

Bronchial asthma is a clinical syndrome characterized by chronic airway inflammation, respiratory symptoms, airflow limitation, and bronchial hypersensitivity \[[@CR1]\]. Asthma has heterogeneous pathogenic causes and can be classified into different phenotypes \[[@CR2], [@CR3]\].

In particular, neutrophilic airway inflammation is found in patients with poorly controlled asthma \[[@CR4]--[@CR6]\]. Neutrophilic asthma is characterized by a high neutrophil count in the sputum (40--76%), along with severe asthma, corticosteroid-insensitivity, chronic airflow obstruction, and acute exacerbation \[[@CR4], [@CR5], [@CR7]--[@CR9]\]. Furthermore, mixed granulocytic (i.e. neutrophilic and eosinophilic) infiltration into the airway causes the greatest disease burden and airflow limitation in asthmatic patients \[[@CR8], [@CR9]\]. Patients with uncontrolled asthma commonly use oral corticosteroid, which may further augment airway neutrophilia. Peripheral blood neutrophilia is another predictor for exacerbation and poor control of asthma \[[@CR10]\], which may be related to oral corticosteroids usage. Importantly, the association between neutrophil counts in sputum and peripheral blood is very weak \[[@CR5]\]. Combined, these results indicate that asthma related to neutrophilic inflammation can be further classified into subtypes, e.g. airway- or blood-dominance and combined. However, no current serum biomarkers efficiently stratify neutrophil-related asthma into subgroups.

Soluble suppression of tumorigenicity 2 (sST2) is a decoy receptor for interleukin (IL)-33 \[[@CR11], [@CR12]\]. IL-33 is released from bronchial epithelial cells and lung blood vessels after exposure to allergic antigens \[[@CR13]\] and necrosis \[[@CR14]\]. IL-33 causes eosinophilic inflammation and Th2 cytokine production in the lungs \[[@CR14]--[@CR17]\] and is involved in arising asthma \[[@CR17], [@CR18]\]. In contrast, sST2 is released from bronchial epithelial cells and lung blood vessels by stimulation with proinflammatory cytokines, toll-like receptor (TLR) ligands, and Th2 cytokines \[[@CR11], [@CR19]\]. Serum sST2 levels are markedly increased when neutrophilic inflammation is present (i.e. in pneumonia \[[@CR20]\], chronic obstructive lung disease \[COPD\], \[[@CR21]\] and sepsis \[[@CR22]\]). In patients with atopic asthma, serum sST2 levels are elevated during exacerbation and are associated with the severity of the asthma attack \[[@CR23]\]. These indicate that the IL-33/sST2 balance affects granulocyte counts in the airway, and that high serum sST2 levels in asthmatics are associated with exacerbation occurrences.

We hypothesized that high serum sST2 levels in stable asthmatics are a predictor for exacerbation within a short period of time. We also expected that serum sST2 levels would stratify neutrophil-related asthma into subgroups. To address these, we conducted a prospective observational study, in which we recruited 104 asthmatic patients, measured serum sST2 levels, followed-up for 3 months, and evaluated whether serum sST2 levels predicted exacerbation. We also explored the characteristics of patients with high serum sST2 levels, and found that serum sST2 levels and blood neutrophilia were independent predictors of asthma exacerbation. In a post-hoc decision, we defined an asthma exacerbation-risk score based on high serum sST2 levels and blood neutrophilia. Patients that were positive for both were at extremely high exacerbation risk (85.7%), indicating that serum sST2 levels and blood neutrophil counts can classify poorly controlled asthma into clinically relevant subgroups.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This was a prospective observational study approved by the institutional review board at Kyorin University (approvals no. 161 and no. 523). All patients gave written informed consent before participating; patients underwent blood tests, lung function tests, and fractional exhaled nitric oxide (FeNO) tests, followed by obtaining exhaled breath condensates (EBC). Afterward, the patients were treated by lung disease specialists in accordance with the guidelines of the Global Initiative for Asthma (GINA) 2015 \[[@CR24]\] and were followed-up for 3 months. The primary endpoint was severe exacerbation: defined as worsening asthma that required hospital admission or an emergency room visit.

Patients {#Sec4}
--------

We recruited patients with asthma who visited the Department of Respiratory Medicine, Kyorin University Hospital from January 2013 through November 2015. All patients were diagnosed with asthma and assessed for treatment step by a lung disease specialist according to the criteria of the GINA 2015. No patients had experienced any exacerbation of asthma for at least 4 weeks prior to participating in the study.

Laboratory testing and cytokine measurements {#Sec5}
--------------------------------------------

Serum levels of sST2, IL-6, IL-8, IL-33, and IL-5 were quantified using Quantikine ELISA kits (R&D Systems, MN, USA) according to the manufacturer's instructions. EBC was obtained with an RTube (Respiratory Research, TX, USA). Serum and EBC H~2~O~2~ levels were measured using a d-ROMs test® (WISMERLL, Tokyo, Japan). The FeNO level was measured using a NIOX MINO® device (Aerocrine AB, Solna, Sweden) according to the manufacturer's instructions and the American Thoracic Society-guidelines \[[@CR25]\].

Statistics {#Sec6}
----------

Normality was assessed using the Shapiro-Wilk test. Data are shown as mean ± SD and median (interquartile range) for parametric and non-parametric data, respectively. For parametric data, two or more groups were compared using the Student's *t*-test or one-way ANOVA, respectively. For non-parametric data, two or more groups were compared using the Mann-Whitney or Kruskal-Wallis tests, respectively. Categorical data were compared using a Chi-square test or Fisher's Exact test. Multiple comparisons for parametric and non-parametric data were performed using the Dunnett test and the Steel test, respectively. For all correlations, the Spearman's correlation coefficient was used. Using the receiver operating characteristic (ROC) curve analysis, the area under curve (AUC) and cut-off values (determined by the Youden index) were calculated. Hazard ratios were calculated using a Cox-regression analysis. Power analysis was performed with an alpha value of 0.05. Statistical analyses were performed using SPSS statistics version 19.0.0 (IBM, New York, USA), SigmaProt version 11.0 (Systat Software Inc., Illinois, USA), and the free website provided by Osaka University (Osaka, Japan; <http://www.gen-info.osaka-u.ac.jp/MEPHAS/steel.html>).

Results {#Sec7}
=======

Characteristics of the patients {#Sec8}
-------------------------------

A total of 104 asthmatic patients were enrolled. During the three-month follow-up period, 11 patients experienced exacerbation (at-risk), whereas 93 patients did not (stable). Triggers of exacerbation were natural worsening of asthma in 10 patients and infection in one. At-risk patients showed poorer control of asthma, a higher treatment step, higher percentage of oral corticosteroid usage, higher WBC and blood neutrophil counts, lower blood eosinophil counts, higher serum H~2~O~2~ and IL-6 levels, and lower percentages of predicted vital capacity (%VC) and forced vital capacity (%FVC) than stable patients (Table [1](#Tab1){ref-type="table"}). Smoking status, serum IgE levels and FeNO did not differ between groups. No patient was treated with biotherapy.Table 1Patient characteristicsStableAt-risk*P*-value\*†(*N* = 93)(*N* = 11)Age, mean (SD)52.7 (15.4)51.7 (19.4)0.852Sex, M: F, *n* (%)39 (42.0): 54 (58.0)3 (27.3): 8 (72.7)0.540BMI, median (IQR)22.9 (20.6--26.9)24.6 (21.8--30.1)0.089Smoking, *n* (%) Current-smoker8 (8.6)2 (18.2)0.454 Ex-smoker27 (29.0)4 (36.4) Never-smoker58 (62.4)5 (45.4)Asthma control, *n* (%) Well controlled29 (31.2)1 (9.1)**\< 0.001** Partially controlled51 (54.8)2 (18.2) Uncontrolled13 (14.0)8 (72.7)Treatment step, *n* (%) 14 (4.3)0 (0.0)**0.008** 214 (15.1)0 (0.0) 320 (21.5)0 (0.0) 449 (52.7)7 (63.6) 56 (6.4)4 (36.4) Oral CS use, *n* (%)6 (6.5)4 (36.4)**0.011**Laboratory tests WBC (/μL), median (IQR)6300 (5000--7200)10,500 (6700--12,100)**\< 0.001** Neutrophil (/μL), median (IQR)3618 (2745--4772)8159 (3953--9196)**\< 0.001** Eosinophil (/μL), median (IQR)201 (128--334)79 (32--303)**0.029** CRP (mg/dl), median (IQR)0.1 (0--0.2)0.1 (0--0.5)0.208 IgE (IU/ml), median (IQR)188 (45--533)185 (12--1539)0.841 IL-8 (pg/ml), median (IQR)13.1 (10.6--16.9)16.0 (9.6--22.6)0.612 IL-6 (pg/ml), median (IQR)1.0 (0.5--1.7)2.4 (1.2--3.7)**0.035** Serum H~2~O~2~ (U.CARR), median (IQR)336 (302--380)379 (350--421)**0.025** FeNO (ppb), median (IQR)24 (16--42)16 (11--99)0.302 EBC H~2~O~2~ (U.CARR), median (IQR)0.5 (0.1--1.0)0.5 (0.2--0.6)0.687Lung function tests VC (L), median (IQR)3.1 (2.5--4.0)2.8 (2.5--4.0)0.067 %VC (%), mean (SD)107.4 (16.1)94.5 (18.9)**0.016** FVC (L), median (IQR)3.0 (2.5--3.9)2.5 (1.9--3.6)0.067 %FVC (%), mean (SD)98.8 (15.6)87.4 (18.7)**0.027** FEV~1~ (L), median (IQR)2.3 (1.8--2.9)1.7 (1.3--2.9)0.104 %FEV~1~ (%), mean (SD)89.6 (19.1)80.1 (26.1)0.135 FEV~1~/FVC (%), median (IQR)75.2 (68.4--81)73.6 (64.3--83.4)0.958\**P*-values for parametric, non-parametric, and categorical data were calculated using the Student's *t*-test, Mann-Whitney test, and Chi-square test, respectively†Bold letters, *P* \< 0.05*BMI* body mass index, *Oral CS* oral corticosteroid, *WBC* white blood cells, *FeNO* fractional exhaled nitric oxide, *EBC* exhaled breath condensate, *SD* standard deviation, *IQR* interquartile range

Serum sST2 levels and high-risk exacerbation patients {#Sec9}
-----------------------------------------------------

At-risk patients showed higher serum sST2 levels than stable patients (*p* = 0.002, Fig. [1a](#Fig1){ref-type="fig"}). A patient with extremely high sST2 levels (364 ng/ml) was exacerbated due to infection within 1 day. Serum sST2 levels correlated positively with treatment step (*r* = 0.258, *p* = 0.008, Fig. [1b](#Fig1){ref-type="fig"}). Serum sST2 levels predicted at-risk patients with an AUC (95% CI) of 0.79 (0.63--0.94) in a ROC curve analysis. A cut-off value of 18.0 ng/ml was diagnostic of patients at high risk of exacerbation (sensitivity 0.73, specificity 0.81), with a hazard ratio (95% confidence interval) of 9.2 (2.4--34.7, *P* = 0.001; Fig. [1c](#Fig1){ref-type="fig"}). Importantly, a power analysis showed that high serum sST2 levels predicted at-risk patients with a power of 0.983 (α = 0.05, *N* = 104, *p* \< 0.001), confirming that this study has a sufficient sample size.Fig. 1Serum sST2 levels and asthma exacerbation risk. **a** Serum sST2 levels were higher in patients whose asthma was exacerbated within 3 months (at-risk) than those without exacerbation (stable). **b** Serum sST2 levels correlated positively with the treatment steps defined in the GINA guidelines (2015). **c** Survival analysis comparing durations until exacerbation between patients with high and low serum sST2 levels. **a**--**c** *p*-values were calculated using the Mann-Whitney test (**a**), Spearman's rank correlation (**b**), and Cox regression analysis (**c**)

These findings demonstrate that serum sST2 levels correlate positively with asthma severity and can diagnose patients at high risk of exacerbation.

Serum sST2 levels and neutrophilic inflammation {#Sec10}
-----------------------------------------------

To explore the characteristics of patients with high serum sST2 levels, we evaluated the correlation between serum sST2 levels and clinical parameters. Serum sST2 levels correlated positively with serum IL-8 levels and airway oxidative stress levels (EBC H~2~O~2~) (Table [2](#Tab2){ref-type="table"}). These findings indicate that serum sST2 levels reflect the extent of airway inflammation and systemic chemotaxis activity. On the other hand, blood neutrophil counts correlated positively with serum CRP, IL-6, oxidative stress (H~2~O~2~) levels, and BMI, and negatively with blood eosinophil (%), serum IgE levels, FeNO levels, and %VC (Table [2](#Tab2){ref-type="table"}). These results suggest that blood neutrophil counts are associated with the extent of systemic inflammation, blood oxidative stress, and obesity, and are strongly associated with neutrophilic inflammation but not eosinophilic or atopic inflammation. Unexpectedly, serum sST2 levels and blood neutrophil counts did not correlate (Table [2](#Tab2){ref-type="table"}). Furthermore, we confirmed that high serum sST2 levels and blood neutrophilia (6000/μl) were independent predictors for asthma exacerbation (Table [3](#Tab3){ref-type="table"}). Importantly, serum sST2 levels were not affected by oral corticosteroid usage, although WBC and blood neutrophil counts were elevated in asthmatics who used regular oral corticosteroid (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). We also measured serum IL-5 and IL-33 levels in 40 subjects as preliminary experiments, but the levels were under the detection limit in all 40 subjects.Table 2Correlations between serum sST2 levels and clinical parametersSerum sST2 level (*N* = 104)Blood neutrophil count (*N* = 104)*rP*-value**\****rP*-value**\***EBC H~2~O~2~ level^a^0.281**0.011**0.0740.513FeNO0.0450.653−0.306**0.002**Serum IL-8 level0.328**0.001**0.0110.915Serum IL-6 level0.0890.3700.384**0.001**Serum CRP level0.0020.9810.305**0.002**Serum IgE level0.0460.643−0.241**0.014**Serum H~2~O~2~ level−0.0990.3180.214**0.029**BMI0.1850.0600.205**0.037**WBC0.1380.1640.901**\< 0.001**Blood neutrophil count0.1290.191NDNDBlood eosinophil count−0.1620.100−0.1870.057Blood neutrophil (%)0.1070.2780.794**\< 0.001\***Blood eosinophil (%)−0.206**0.036\***− 0.409**\< 0.001\***\*Bold letters, *P* \< 0.05 calculated using Spearman rank correlation^a^*N* = 81*R* = correlation coefficient, *FeNO* fractional exhaled nitric oxide, *EBC* exhaled breath condensate, *WBC* white blood cellTable 3Multivariate analysis for predicting the risk of asthma exacerbationUnivariateMultivariate^a^Hazard ratio (95% CI)*P*-valueHazard ratio (95% CI)*P*-value\*High serum sST2 level (\> 18 ng/ml)9.2 (2.4--34.7)0.0015.5 (1.4--21.5)0.015Blood neutrophilia^b^ (\> 6000 μl)26.6 (7.9--100.9)\< 0.00118.9 (4.8--74.4)\< 0.001\**P*-values were calculated using Cox proportional hazard analysis^a^Correlation coefficients: high serum sST2 level, 1.70; blood neutrophilia, 2.94, respectively^b^The cut-off value for defining blood neutrophilia was optimized using the receiver operating characteristic curve analysis and calculating the Youden index*CI* confidence interval

Taken together, high serum sST2 levels and blood neutrophilia reflect airway and systemic inflammation, respectively, and are independent predictors for asthma exacerbation.

Definition of exacerbation-risk score and the score-based phenotypes {#Sec11}
--------------------------------------------------------------------

With a post-hoc decision, we defined an exacerbation-risk score for asthma based on serum sST2 levels and blood neutrophil count (Fig. [2a](#Fig2){ref-type="fig"}). The exacerbation-risk score predicted asthma worsening with an AUC of 0.91 (*P* \< 0.001, Fig. [2b](#Fig2){ref-type="fig"}) in the ROC curve analysis. The odds ratios of scores 1 to 3 for predicting exacerbation were 8.4 (*P* = 0.109), 35.5 (*P* = 0.014), and 426 (*P* \< 0.001), respectively (Fig. [2c](#Fig2){ref-type="fig"}). A survival curve analysis also showed that patients with scores of 2 and 3 were at higher risk of exacerbation than patients with scores of 0 (Fig. [2d](#Fig2){ref-type="fig"}). The sensitivities and specificities of each score for predicting exacerbation are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1. Importantly, a power analysis showed that high exacerbation-risk score predicted at-risk patients with a power of 1.000 (α = 0.05, *N* = 104, *P* \< 0.001), confirming that this study has a sufficient sample size.Fig. 2The exacerbation-risk score and its accuracy. **a** Definition of the exacerbation-risk score. Scores of 1 and 2 were based on the coefficients calculated in Table [3](#Tab3){ref-type="table"} (high serum sST2 level, 1.70; blood neutrophilia, 2.94) (**b**) The exacerbation-risk score predicted asthma exacerbation with an AUC (95% CI) of 0.91 (0.79--1.02) (*P* \< 0.001) in the ROC curve analysis. **c** Odds ratios predicting exacerbation risk for scores of 1, 2, and 3 as compared with a score of 0. **d** Survival analysis comparing time to exacerbation among patients with scores ranging from 0 to 3. *P* \< 0.05: score 0 vs. 2, score 0 vs. 3, and score 1 vs. 2. (B--D) *P*-values were calculated using a ROC curve analysis (**b**), Fisher's Exact test (**c**), and Log-Rank test (**d**). CI, confidence interval

Finally, we assessed the characteristics of patients with each score (Table [4](#Tab4){ref-type="table"}). Patients with a score of 3, with both high serum sST2 levels and blood neutrophilia, showed the most severe phenotype. Six out of seven patients (85.7%) experienced exacerbation; their asthma was mostly uncontrolled rather than in intensive treatment (a high treatment step), with airflow limitation and a lower percentage of eosinophil in WBC. Patients with a score of 2, with blood neutrophilia alone, showed a 33.3% exacerbation rate, identical treatment step, and better asthma control compared to patients with a score of 3, and preserved lung function, indicating that they were relatively reactive to corticosteroids. Patients with a score of 1, with high serum sST2 levels alone, showed a 10.5% of exacerbation rate, higher serum IL-8 levels, and a slightly higher treatment step than those with a score of 0. Patients with a score of 0, without serum sST2 level elevation nor blood neutrophilia, were at the lowest exacerbation risk (1.4% exacerbation rate).Table 4Characteristics of patients classified with the exacerbation-risk scoreExacerbation-risk score*P*-value\*0123(*N* = 72)(*N* = 19)(*N* = 6)(*N* = 7)Patients with exacerbation of asthma, *n* (%)1 (1.4)2 (10.5)2 (33.3)6 (85.7)**\< 0.001**Age, mean (SD)54.1 ± 14.656.1 ± 17.347.2 ± 20.059.7 ± 18.40.321Sex, M: F, *n* (%)24 (33.8): 48 (66.7)13 (68.4): 6 (31.6)2 (33.3): 4 (66.7)3 (42.9): 4 (57.1)0.050BMI, median (IQR)22.9 (20.6--27.4)23.1 (21.5--26.7)23.1 (19.6--28.6)27.9 (21.8--30.1)0.538Smoking, *n* (%) Current smoker8 (11.1)1 (5.3)0 (0)1 (28.6)0.527 Ex-smoker19 (26.4)6 (31.6)4 (66.7)2 (14.3) Never-smoker45 (62.5)12 (63.2)2 (33.3)4 (57.1)Asthma control, *n* (%) Well controlled20 (27.8)7 (36.8)3 (50.0)0 (0)**\< 0.001** Partially controlled42 (58.3)9 (47.4)1 (16.7)1 (14.3) Uncontrolled10 (13.9)3 (15.8)2 (33.3)6 (85.7)Treatment step, *n* (%) 14 (5.5)0 (0.0)0 (0.0)0 (0.0)**0.005** 211 (15.3)1 (5.3)1 (16.7)1 (14.2) 316 (22.2)4 (21.0)0 (0.0)0 (0.0) 439 (54.2)12 (63.2)2 (33.3)3 (42.9) 52 (2.8)2 (10.5)3 (50.0)3 (42.9)sST2 (ng/ml), median (IQR)11.0 (8.8--13.0)21.1 (18.8--28.4)11.8 (11.4--14.3)26.4 (20.8--34.0)**\< 0.001**WBC (/μL), median (IQR)6200 (5225--6800)5900 (4700--7200)10,250 (9000--12,350)10,500 (9700--12,100)**\< 0.001**Neutrophil (/μL), median (IQR)3496 (2786--4268)3553 (2248--4650)6333 (6117--10,381)8159 (7497--9196)**\< 0.001**Eosinophil (/μL), median (IQR)199 (133--335)201 (45--307)229 (75--677)87 (32--303)0.273Eosinophil (%), median (IQR)3.7 (2.1--6.2)3.4 (0.9--4.9)2.4 (0.6--7.4)**1.0 (0.3--2.5) †0.045**CRP (mg/dl), median (IQR)0.1 (0--0.2)0.0 (0--0.)0.1 (0--0.4)0.1 (0.1--0.5)0.195IgE (IU/ml), median (IQR)201 (45--684)236 (104--330)60 (8--843)73 (3--2656)0.432IL-8 (pg/ml), median (IQR)13.0 (10.5--15.8)**21.9 (9.7--31.0) †**11.7 (7.9--19.8)16.0 (11.0--25.2)0.063IL-6 (pg/ml), median (IQR)1.0 (0.5--1.8)0.9 (0.5--1.9)2.5 (1.2--8.0)1.8 (0.3--3.7)0.143Serum H~2~O~2~ (U. CARR), median (IQR)345 (315--401)322 (294--356)341 (304--390)383 (336--390)0.182FeNO (ppm), median (IQR)23.5 (16.0--38.3)24.0 (15.0--63.0)19.0 (13.3--49.8)16.0 (11.0--121.0)0.892EBC H~2~O~2~ (U. CARR) ^a^0.4 (0.0--1.0)0.5 (0.2--1.1)0.4 (0.0--0.6)0.6 (0.3--0.7)0.751VC (L), median (IQR)2.9 (2.5--3.8)3.7 (2.6--4.4)3.7 (3.3--3.8)**2.3 (2.0--2.9) †**0.079%VC (%), mean (SD)106.7 (45.6)107.9 (19.5)114.0 (13.0)**87.3 (14.2) ‡0.014**FVC (L), median (IQR)2.9 (2.4--3.7)3.7 (2.5--4.4)3.6 (3.2--3.8)**2.2 (1.8--2.9) †**0.087%FVC (%), mean (SD)98.6 (14.6)97.1 (15.4)107.1 (15.4)**79.4 (12.1) ‡0.009**FEV~1~ (L), median (IQR)2.3 (1.8--2.7)2.5 (1.4--3.1)2.8 (2.0--3.0)1.6 (1.3--1.9)0.142%FEV~1~ (%), mean (SD)90.1 (17.8)86.5 (23.5)97.7 (24.3)**71.1 (22.3) ‡**0.063FEV~1~/FVC (%), median (IQR)76.0 (69.2--81.0)70.3 (67.6--79.8)79.4 (66.0--82.0)73.6 (64.0--83.6)0.550\**P*-values for parametric, non-parametric, and categorical data were calculated using a one-way ANOVA test, Kruskal-Wallis test, and Chi-square test, respectively†*P* \< 0.05 vs. a score of 0, calculated using the Steel test‡*P* \< 0.05 vs. a score of 0, calculated using the Dunnett test\*†‡ Bold letters, *P* \< 0.05^a^A total of 81 patients (scores of 0, 1, 2, and 3: *N* = 56, 17, 4, and 4, respectively) were evaluated*BMI* body mass index, *WBC* white blood cells, *FeNO* fractional exhaled nitric oxide, *EBC* exhaled breath condensate, *SD* standard deviation, *IQR* interquartile range

Taken together, high serum sST2 levels (greater than 18 ng/ml) are reasonable predictor of exacerbation and, when combined with blood neutrophilia, provided an exacerbation risk score that is an accurate predictor of exacerbation and which classifies poorly-controlled asthma into subgroups.

Discussion {#Sec12}
==========

The present study demonstrated that serum sST2 levels serve as a biomarker for the disease severity of asthma and predicted exacerbation risk within 3 months. Serum sST2 levels reflected the extent of airway oxidative stress and serum chemotaxis activity, whereas peripheral neutrophil counts reflected systemic inflammatory response, blood oxidative stress, and obesity. High serum sST2 levels and peripheral blood neutrophilia independently predicted asthma exacerbation, and a double positive was suggestive of an extremely high risk of worsening asthma, corticosteroid-resistance, and airflow limitation.

High serum sST2 levels serve as biomarker for asthma severity. Oshikawa and colleagues evaluated atopic asthma patients and reported that serum sST2 levels during exacerbation were higher than these at steady state and were associated with asthma severity (i.e. peak flow volume and arterial blood CO~2~ partial pressure) \[[@CR23]\]. We assessed asthmatic patients who were recruited irrespective of atopic state and demonstrated that serum sST2 levels at steady state also correlated with disease severity (i.e. treatment step) and that serum sST2 levels greater than 18 ng/ml were a reasonable predictor for exacerbation within 3 months. Taken together, serum sST2 levels in asthmatics correlate with severity at steady state and during exacerbation, and are a reasonable predictor for exacerbation regardless of atopic state.

sST2 is produced in the lungs \[[@CR11], [@CR19]\]. Multiple types of human lung cells (i.e. bronchial cells, alveolar cells, and vascular endothelial cells) release sST2 in vitro, which can be enhanced by stimulation with proinflammatory cytokines, lipopolysaccharide, and Th2 cytokines \[[@CR11], [@CR19]\]. Serum (or plasma) sST2 levels were elevated in patients with neutrophilic (i.e. bacterial pneumonia \[[@CR20]\] and COPD \[[@CR21]\]) and eosinophilic (i.e. acute eosinophilic pneumonia \[[@CR26]\]) lung disease. Serum sST2 levels correlated with disease severity in pneumonia patients \[[@CR20]\]. These suggest that serum sST2 levels reflect the extent of airway inflammation. In addition, airway H~2~O~2~ levels correlate with sputum granulocyte (i.e. neutrophil and eosinophil) counts in asthmatic patients \[[@CR27]\]. We demonstrated the positive correlation between serum sST2 levels and airway H~2~O~2~ levels in asthmatics, which also indicated an association between high serum sST2 levels and the presence of airway inflammation. Taken together, serum sST2 levels reflect the extent of neutrophil and/or eosinophil infiltration in lungs.

Neutrophilic inflammation is associated with the development of uncontrolled asthma. Airway neutrophilic inflammation is related to severe asthma; airway mixed-granulocytic infiltration (i.e. both neutrophils and eosinophils) appeared to cause the greatest disease burden in asthmatics \[[@CR8], [@CR9]\]. In addition to sputum neutrophilia, peripheral blood neutrophilia was also a risk factor for asthma worsening \[[@CR10]\]. However, blood neutrophil counts showed only a low association with sputum neutrophil count \[[@CR5], [@CR28]\], suggesting that neutrophilic inflammation-related asthma could be further classified (e.g. into subgroups of airway-dominant, blood-dominant, and mixed neutrophilia). We classified asthmatics into four subtypes using blood neutrophilia (related to systemic inflammation) and high serum sST2 levels (associated with airway inflammation), which provided an accurate predictor for exacerbation (the exacerbation-risk score). These support the concept that neutrophil-related asthma can be further stratified into subgroups that reflect phenotypic severity. Although further investigation regarding the relationship between sputum granulocyte counts (i.e. neutrophil and eosinophil counts) and serum sST2 levels are needed, our observations indicate that sST2 is a potential phenotypic marker for uncontrolled asthma.

IL-33 is related to eosinophilic asthma: it is the nuclear-associated cytokine of IL-1, \[[@CR29]\] which is released from allergen-exposed cells \[[@CR13]\]. Exogenous administration of IL-33 causes a massive infiltration of eosinophils and Th2 cytokine production \[[@CR14]--[@CR16]\]. In addition, IL-33 stimulates type 2 innate lymphoid cells to produce IL-5 and -13 resulting in eosinophilia and goblet cell hyperplasia, respectively \[[@CR16]\]. Genome-wide association studies (GWASs) have demonstrated that *IL-33* and *IL1RL1* (encoding the IL-33 receptor) variants were associated with arising asthma \[[@CR17], [@CR18]\] and blood eosinophilia \[[@CR17]\]. The *IL-1RL1* variant was also associated with arising neutrophilic asthma whereas the *IL-33* variant was not \[[@CR17]\]. Further, some *IL1RL1* variants enhance sST2 production, as demonstrated by human plasma analysis and cell culture experiments \[[@CR30]\]. Our data show that high serum sST2 levels are related to low blood eosinophil (%), which was also associated with less airway eosinophilic inflammation \[[@CR22]\]. Taken together, an interaction between IL-33, the cell surface, and soluble IL-33 receptors (ST2L and sST2, respectively) regulates the airway granulocyte (i.e. neutrophil and eosinophil) counts that potentially influence asthma phenotypes.

The sST2/IL-33 axis regulates neutrophilic inflammation in the lungs \[[@CR29], [@CR31]\]. In a mouse model of influenza virus infection, IL-33 synthesis increased in the lungs \[[@CR32]\]. Similarly, in a mouse COPD exacerbation model caused by influenza virus infection, nasal administration of IL-33 enhanced neutrophil infiltration into lungs, which was attenuated by sST2 administration \[[@CR33]\]. IL-33, known as alarmine, \[[@CR34]\] is released from necrotized cells \[[@CR11]\]. IL-33 is processed by neutrophil elastase from a less-active full-length form to a highly-activated cleaved form \[[@CR35]\]. IL-33 restored a decrease in neutrophil chemotaxis that resulted from TLR stimulation \[[@CR31]\]. Thus, IL-33 augments neutrophilic airway inflammation in certain situations, such as when viral infections accompany necrotic tissue damage. Importantly, inflamed epithelial cells release an increased amount of sST2 \[[@CR11], [@CR19]\]. This attenuates biologically IL-33-induced neutrophilic inflammation and serves clinically as a biomarker for lung inflammation. Taken together, the sST2/IL-33 balance is regulated in the lungs, controlling neutrophilic inflammation and subsequent tissue damage, and serving as a biomarker for airway inflammation.

This study has some limitations. First, it is a relatively small-scale and single-centre study, thus, our findings require further confirmation by a larger study. Second, we did not evaluate sputum cells nor serum IL-33 levels. The relationship among serum sST2 and IL-33 levels, blood neutrophil counts, and asthma phenotypes should also be evaluated with sputum cell counts in future studies. However, our study provides novel diagnostic methods that counter these limitations. Firstly, serum sST2 levels greater than 18 ng/ml were a reasonable predictor for exacerbation within 3 months. Secondly, high serum sST2 levels and blood neutrophilia provided an exacerbation-risk score that can classify neutrophil-related asthma into subgroups where the subgroup with the highest score had an 85.7% exacerbation rate.

Conclusion {#Sec13}
==========

High serum sST2 levels predict exacerbation in the general asthmatic population and, when combined with blood neutrophil levels, provide an exacerbation-risk score that is a better predictor of exacerbation than serum sST2 levels alone.
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